TNG Stock Overview
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
Transgene SA Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€1.80|
|52 Week High||€2.55|
|52 Week Low||€1.64|
|1 Month Change||5.76%|
|3 Month Change||-6.84%|
|1 Year Change||-15.98%|
|3 Year Change||38.52%|
|5 Year Change||-40.56%|
|Change since IPO||-96.01%|
Recent News & Updates
Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near TermMar 21
Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMar 19
Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?Mar 18
Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?Nov 24
Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?Apr 16
What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?Mar 12
Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?Jan 23
|TNG||FR Biotechs||FR Market|
Return vs Industry: TNG underperformed the French Biotechs industry which returned -8% over the past year.
Return vs Market: TNG underperformed the French Market which returned 16.8% over the past year.
|TNG Average Weekly Movement||3.0%|
|Biotechs Industry Average Movement||5.8%|
|Market Average Movement||3.8%|
|10% most volatile stocks in FR Market||9.5%|
|10% least volatile stocks in FR Market||2.0%|
Stable Share Price: TNG is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: TNG's weekly volatility (3%) has been stable over the past year.
About the Company
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
Transgene SA Fundamentals Summary
|TNG fundamental statistics|
Is TNG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TNG income statement (TTM)|
|Cost of Revenue||€32.17m|
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Sep 20, 2023
|Earnings per share (EPS)||-0.33|
|Net Profit Margin||-320.63%|
How did TNG perform over the long term?See historical performance and comparison